An Integrated Care Platform Based on the Monitoring of Older Individual Intrinsic Capacity for Inclusive Health (CAREUP)

NCT ID: NCT05963399

Last Updated: 2024-03-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-30

Study Completion Date

2024-12-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to assess the usability and acceptance of the CAREUP solution in improving the quality of life at home of the older adults. The CAREUP solution is a platform that collects data from different tools such as tablets, smartwatches, ambient sensors, iHealth weight scale, and Digital Hand Dynamometer.

.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to assess the usability and acceptance of the CAREUP solution at home in primary (older adults), secondary (informal caregivers) and tertiary (doctors and geriatrics) end users. The CAREUP solution is a platform that collects data from different tools such as tablets, smartwatches, ambient sensors, iHealth weight scale, and Digital Hand Dynamometer. The study will comprehends two phases: a pre-pilot and pilot phases.The pre-pilot phase will test new user interfaces and games with 5 older adult (primary users) and 5 informal caregiver (secondary) in each site (Italy, Romania, Austria) for at least 1 week. This phase will only focus on primary endpoints (usability and acceptance). The pilot phase will investigate platform usability, acceptance and efficiency of developed Intrinsic Capacity (IC) evaluation algorithms, reliability and security. At least 30 primary and 15 secondary and some tertiary users (doctors and geriatrics) will be enrolled in each country (Italy, Romania, Austria) for 12 months. This phase will focus on both primary and secondary endpoints.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Old Age

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

older adults

Elderly adults who live independently in their own home in rural or urban areas.

Group Type EXPERIMENTAL

CAREUP platform

Intervention Type DEVICE

The Experimental Group will test the CAREUP platform at home for 12 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CAREUP platform

The Experimental Group will test the CAREUP platform at home for 12 months.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Live independently in their home in rural or urban areas;
* In good physical and cognitive status;
* Able to stand and walk unaided;
* Availability to sign the Informed Consent;
* Ability to use smartphones/tablets independently.

Exclusion Criteria

* Use of active implant or not-implant medical devices;
* Allergy to nickel components;
* Lack of written informed consent;
* Acute or untreated medical problems such as history of syncopal episodes, epilepsy and vertigo not controlled pharmacologically; serious dysfunction of the autonomic system; severe behavioural syndromes not compensated by drugs; concurrent neurological diseases; severe systemic diseases with life expectancy \< 1 year;
* A myocardial infarction or stroke within 6 months;
* Painful arthritis, spinal stenosis, amputation, painful foot lesions or neuropathy limiting balance and mobility;
* Uncontrolled hypertension;
* Pacemaker or implantable cardioverter defibrillator;
* Diagnosis of mild and or/advanced Parkinson's disease or other neuromuscular disorder;
* Diagnosis of mild and/or advance cognitive impairments
* Metastatic cancer or immunosuppressive therapy;
* Significant visual or hearing impairment
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Union

OTHER

Sponsor Role collaborator

Istituto Nazionale di Ricovero e Cura per Anziani

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vera Stara

Role: STUDY_CHAIR

IRCCS INRCA, Ancona, Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

EURAG Austria

Vienna, , Austria

Site Status

IRCCS INRCA Hospital

Ancona, , Italy

Site Status

Ana Aslan International Foundation

Bucharest, , Romania

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Italy Romania

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anna Rita Bonfigli

Role: CONTACT

+390718003719

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Eva Reither

Role: primary

Vera Stara

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

INRCA_007_2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.